Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

charles river laboratories international inc. - CRL

CRL

Close Chg Chg %
186.06 1.89 1.01%

Closed Market

187.95

+1.89 (1.01%)

Volume: 648.10K

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Trade Now

Company Overview: charles river laboratories international inc. - CRL

CRL Key Data

Open

$187.92

 Day Range

183.55 - 188.32

52 Week Range

176.48 - 274.83

 Market Cap

$9.52B

Shares Outstanding

51.14M

 Public Float

50.59M

Beta

1.38

 Rev. Per Employee

N/A

P/E Ratio

22.98

 EPS

$8.15

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

879.04K

  

CRL Performance

1 Week
 
 0.09%
 
1 Month
 
 -4.99%
 
3 Months
 
 -8.46%
 
1 Year
 
 -4.58%
 
5 Years
 
 33.48%
 

CRL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About charles river laboratories international inc. - CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

CRL At a Glance

Charles River Laboratories International, Inc.
251 Ballardvale Street
Wilmington, Massachusetts 01887
Phone 1-781-222-6000 Revenue 4.13B
Industry Miscellaneous Commercial Services Net Income 474.62M
Sector Commercial Services 2023 Sales Growth 3.857%
Fiscal Year-end 12 / 2024 Employees 21,800
View SEC Filings

CRL Valuation

P/E Current 22.98
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.627
Price to Sales Ratio 2.945
Price to Book Ratio 3.374
Price to Cash Flow Ratio 17.785
Enterprise Value to EBITDA 15.452
Enterprise Value to Sales 3.649
Total Debt to Enterprise Value 0.207

CRL Efficiency

Revenue/Employee 189,422.431
Income Per Employee 21,771.743
Receivables Turnover 5.292
Total Asset Turnover 0.523

CRL Liquidity

Current Ratio 1.525
Quick Ratio 1.164
Cash Ratio 0.268

CRL Profitability

Gross Margin 33.703
Operating Margin 16.01
Pretax Margin 14.077
Net Margin 11.494
Return on Assets 6.009
Return on Equity 14.441
Return on Total Capital 7.059
Return on Invested Capital 7.453

CRL Capital Structure

Total Debt to Total Equity 86.932
Total Debt to Total Capital 46.505
Total Debt to Total Assets 38.156
Long-Term Debt to Equity 85.251
Long-Term Debt to Total Capital 45.605
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Charles River Laboratories International Inc. - CRL

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
2.92B 3.54B 3.98B 4.13B
Sales Growth
+11.55% +21.08% +12.31% +3.86%
Cost of Goods Sold (COGS) incl D&A
1.96B 2.33B 2.66B 2.74B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
234.92M 265.54M 303.87M 314.12M
Depreciation
123.05M 140.68M 157.29M 176.68M
Amortization of Intangibles
111.88M 124.86M 146.58M 137.44M
COGS Growth
+12.00% +18.91% +14.14% +2.92%
Gross Income
964.02M 1.21B 1.32B 1.39B
Gross Income Growth
+10.64% +25.48% +8.80% +5.75%
Gross Profit Margin
+32.97% +34.17% +33.10% +33.70%
2020 2021 2022 2023 5-year trend
SG&A Expense
505.06M 607.21M 663.49M 730.61M
Research & Development
- - - -
-
Other SG&A
505.06M 607.21M 663.49M 730.61M
SGA Growth
+5.50% +20.22% +9.27% +10.12%
Other Operating Expense
- - - -
-
Unusual Expense
(54.16M) 10.44M 25.20M 43.87M
EBIT after Unusual Expense
513.11M 591.99M 627.38M 617.26M
Non Operating Income/Expense
11.11M (3.24M) 104.61M 100.73M
Non-Operating Interest Income
834.00K 652.00K 780.00K 5.20M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
77.11M 108.04M 109.00M 136.71M
Interest Expense Growth
-3.07% +40.12% +0.89% +25.42%
Gross Interest Expense
77.11M 108.04M 109.00M 136.71M
Interest Capitalized
- - - -
-
Pretax Income
447.11M 480.71M 622.99M 581.28M
Pretax Income Growth
+47.04% +7.51% +29.60% -6.69%
Pretax Margin
+15.29% +13.58% +15.67% +14.08%
Income Tax
81.81M 81.87M 130.38M 100.91M
Income Tax - Current - Domestic
44.81M 41.98M 94.84M 66.91M
Income Tax - Current - Foreign
35.41M 60.20M 68.64M 85.36M
Income Tax - Deferred - Domestic
(4.00M) (34.20M) (31.97M) (52.13M)
Income Tax - Deferred - Foreign
5.58M 13.89M (1.13M) 779.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
365.31M 398.84M 492.61M 480.37M
Minority Interest Expense
1.00M 7.86M 6.38M 5.75M
Net Income
364.30M 390.98M 486.23M 474.62M
Net Income Growth
+44.55% +7.32% +24.36% -2.39%
Net Margin Growth
+12.46% +11.04% +12.23% +11.49%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
364.30M 390.98M 486.23M 474.62M
Preferred Dividends
- - - -
-
Net Income Available to Common
364.30M 390.98M 486.23M 474.62M
EPS (Basic)
7.3522 7.7741 9.5691 9.2651
EPS (Basic) Growth
+42.16% +5.74% +23.09% -3.18%
Basic Shares Outstanding
49.55M 50.29M 50.81M 51.23M
EPS (Diluted)
7.1981 7.603 9.4779 9.2248
EPS (Diluted) Growth
+41.93% +5.63% +24.66% -2.67%
Diluted Shares Outstanding
50.61M 51.42M 51.30M 51.45M
EBITDA
693.88M 867.97M 956.46M 975.26M
EBITDA Growth
+17.47% +25.09% +10.19% +1.97%
EBITDA Margin
+23.73% +24.52% +24.06% +23.62%

Snapshot

Average Recommendation HOLD Average Target Price 215.313
Number of Ratings 20 Current Quarters Estimate 2.54
FY Report Date 12 / 2024 Current Year's Estimate 10.176
Last Quarter’s Earnings 2.59 Median PE on CY Estimate N/A
Year Ago Earnings 10.67 Next Fiscal Year Estimate 10.32
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 13 18 18
Mean Estimate 2.54 2.38 10.18 10.32
High Estimates 2.65 2.68 10.31 10.80
Low Estimate 2.44 2.19 9.93 9.18
Coefficient of Variance 2.33 4.90 0.90 3.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 7
OVERWEIGHT 1 1 1
HOLD 11 11 12
UNDERWEIGHT 1 1 0
SELL 2 2 0
MEAN Hold Hold Overweight

Insider Actions for Charles River Laboratories International Inc. - CRL

Date Name Shares Transaction Value
Jun 5, 2024 Shannon M. Parisotto CEVP, Disc & Safety Assessment 3,925 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 James C. Foster Chairman, President and CEO; Director 24,858 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Victoria L. Creamer EVP & Chief People Officer 4,470 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Victoria L. Creamer EVP & Chief People Officer 14,829 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Birgit Girshick Corporate Executive VP & COO 50,512 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Flavia H. Pease Corporate Executive VP & CFO 9,760 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Joseph W. LaPlume EVP, Corp Strategy & Develop 24,301 Bona fide gift 0.00
Jun 5, 2024 Flavia H. Pease Corporate Executive VP & CFO 4,906 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Birgit Girshick Corporate Executive VP & COO 8,722 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Shannon M. Parisotto CEVP, Disc & Safety Assessment 8,406 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Joseph W. LaPlume EVP, Corp Strategy & Develop 4,797 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Michael Gunnar Knell CSVP&Chief Accounting Officer 8,326 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Michael Gunnar Knell CSVP&Chief Accounting Officer 1,472 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 31, 2024 William D. Barbo Corporate Executive VP & CCO 3,612 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $217.21 per share 784,562.52
May 31, 2024 Victoria L. Creamer EVP & Chief People Officer 13,052 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $217.21 per share 2,835,024.92
May 31, 2024 William D. Barbo Corporate Executive VP & CCO 3,711 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $217.21 per share 806,066.31
May 31, 2024 William D. Barbo Corporate Executive VP & CCO 3,858 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $217.21 per share 837,996.18
May 31, 2024 William D. Barbo Corporate Executive VP & CCO 3,433 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $214.51 per share 736,412.83
May 31, 2024 James C. Foster Chairman, President and CEO; Director 223,044 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $214.51 per share 47,845,168.44
May 30, 2024 Michael Gunnar Knell CSVP&Chief Accounting Officer 404 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Charles River Laboratories International Inc. in the News